

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/562,296-Conf. #3685
				Filing Date	December 24, 2006
				First Named Inventor	Peter W. Gage
				Art Unit	1625
				Examiner Name	N. S. Chandrakumar
Sheet	1	of	2	Attorney Docket Number	64681(70403)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/NC/		US-2,734,904	02-14-1956	G. D. Searle & Co.	
		US-3,313,813	04-11-1967	Merck & Co.	
		US-3,527,758	09-08-1970	Merck & Co.	
NC		US-6,133,247	10-17-2000	University of North Carolina	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/NC/		JP-2002-528460	09-03-2002			
		JP-2002-527397	08-27-2002			
		JP-2003-563559	03-12-2003			
		JP-2003-73280	12-03-2003			
		JP-2005-522425	07-28-2005			
		JP-H7-25768	01-27-1995			
		JP-H7-89859	04-04-1995			
		JP-H8-225513	09-03-1996			
		JP-H9-67332	11-03-1997			
		WO-99/31267	06-24-1999			
		WO-00/21538	04-20-2000			
/NC/		WO-01/12805	02-22-2001			

Examiner Signature	/Nizal S. Chandrakumar/	Date Considered	12/10/2010
--------------------	-------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/562,296-Conf. #3685
				Filing Date	December 24, 2006
				First Named Inventor	Peter W. Gage
				Art Unit	1625
				Examiner Name	N. S. Chandrakumar
Sheet	2	of	2	Attorney Docket Number	64681(70403)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/NC/		Ahmed et al., Arylcyclopropanecarboxyl Guanidines as Novel, Potent, and Selective Inhibitors of the Sodium Hydrogen Exchanger Isoform-1, Journal of Medicinal Chemistry, 2001, Vol. 44, No. 20, pp. 3302-3310		
		Ewart et al., Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu, European Biophysics Journal, 2002, Vol. 31, No. 1, pp 26-35		
		Ewart et al., "Potential New Anti-Human Immunodeficiency Virus Type 1 Compounds Depress Virus Replication in Cultured Human Macrophages, Antimicrobial Agents Chemotherapy., 2004, Vol. 48, No. 6, pp: 2325-30		
		Giacometti et al., In vitro anti-cryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems, J. Antimicrob. Chemotherapy, 2000, Vol. 45, No. 5, pp: 651-4		
		Goerdeler and Mertens, 1,2,4-Thiadiazoles, XX. A Study of 3-Amino-thiadiazoles, Chemische Berichte, 1970, Vol. 103, No. 6, pp. 1805-1814		
		Hennrich et al., Fluorescent anion receptors with iminoylthiourea binding sites-selective hydrogen bond mediated recognition of C032-, HC03- and HP042-, Tetrahedron Letters, 2001, Vol. 42, No.15, pp.2805-2808		
		Rogister et al., "Novel inhibitors of the sodium-calcium exchanger: benzene ring analogues of N-guanidino substituted amiloride derivatives, European Journal of Medicinal Chemistry, 2001, Vol. 36, No. 7-8, pp. 597-614.		
/NC/		Yamamoto et al., Structural Requirements for Potent Na/H Exchange inhibitors Obtained from Quantitative Structure-Activity Relationships of Monocyclic and Bicyclic Arolylguanidines, Chemical & Pharmaceutical Bulletin, 1997, Vol. 45, No. 8, pp. 1282-1286		

Examiner Signature	/Nizal S. Chandrakumar/	Date Considered	12/10/2010
-----------------------	-------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.